Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 102 + panitumumab for recurrent glioblastoma multiforme
ACTRN12610000092099Phase 2Terminated
- Sponsor
- University of Sydney
- Start
- Apr 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rilotumumab and panitumumab in glioblastoma (GBM), sponsored by University of Sydney. Primary endpoint: Six-month progression-free survival. Started Apr 2010; status: terminated.
02
Drugs
rilotumumabpanitumumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ACTRN12610000092099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000092099.